Debra trial deescalating radiation for invasive DCIS
I recently was diagnosed with invasive DCIS and my surgeon told me that there is trial called the Debra trial I may qualify for. I have invasive DCIS stage 1 grade 1 ER+ and HER2- and it is smaller than 2cm. This so far qualifies me and the next step is to see if my oncotype gene score is between 1-18 and also would need an sentinal node biospy that shows no lymph node involvement. Has anyone else heard of or considered this trial? It is very interesting as the goal of the trial is to see if women with my same diagnosis can safely omit radiation with a lumpecotmy and estrogen blockers alone and have the same risk of recurrence as someone who has a lumpectomy with estrogen blockers and radiation.
Comments
-
Hi @lcslcs and welcome.
The study's full name is called NRG-BR007 (the DEBRA trial). It’s looking at whether some people with low-risk, DCIS or Stage I, ER+ / HER2- breast cancer can safely skip radiation after lumpectomy and use endocrine therapy alone, without increasing recurrence risk.In general, it’s for people with:
- Tumor ≤2 cm, node-negative
- ER+ / HER2-
- Low genomic risk (Oncotype DX ≤18)
- After lumpectomy
Participants are randomized to radiation + endocrine therapy or endocrine therapy alone.
Many people with similar low-risk diagnoses are hearing about this as part of radiation “de-escalation” research. Would love to hear from anyone else here who may have been offered or considered the DEBRA (NRG-BR007) trial.
How are you feeling about it @lcslcs ?0
